Skip to Main content Skip to Navigation
Journal articles

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

Abstract : Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC 50 ) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03258933
Contributor : Patrice Bruscella <>
Submitted on : Saturday, June 12, 2021 - 10:08:12 AM
Last modification on : Tuesday, June 15, 2021 - 3:26:24 AM

Links full text

Identifiers

Collections

Citation

Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, et al.. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2020, 64 (7), pp.e00876-20. ⟨10.1128/AAC.00876-20⟩. ⟨inserm-03258933⟩

Share

Metrics

Record views

11